Newsroom

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations...

休斯顿--(BUSINESS WIRE)--(美国商业资讯)-- SLB (NYSE:SLB)将于2026年4月24日举行电话会议，讨论截至2026年3月31日的第一季度业绩。 本次电话会议定于美国东部时间上午11:00开始，相关业绩新闻稿将于美国东部时间上午7:00发布。 如需接入电话会议，参会者需在会议开始前约10分钟联系电话会议接线员：北美地区请拨打+1 (833) 470-1428，北美以外地区请拨打+1 (404) 975-4839，接入码为742955。 会议将通过https://events.q4inc.com/attendee/972985185进行同步网络直播（仅限收听）。参会者需在会议开始前15分钟登录以测试浏览器并完成网络直播注册。电话会议结束后，将在www.slb.com/irwebcast网站上提供回放至2026年5月1日；也可通过电话收听回放，在北美地区拨打+1 (866) 813-9403，在北美以外地区拨打+1 (929) 458-6194，输入接入码360731即可收听。 关于SLB SLB (NYSE: SLB)是一家全球科技公司，百年来始终致力于推...

NEW YORK--(BUSINESS WIRE)--If you suffered a loss on your investment inPayPal Holdings, Inc. (“PayPal” or the “Company”) (NASDAQ:PYPL), contact Lauren Molinaro by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 20, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff ove...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans...

中国北京--(BUSINESS WIRE)--(美国商业资讯)-- 百奥赛图（北京）医药科技股份有限公司（以下简称“百奥赛图”，SSE: 688796；HKEX: 02315），一家以创新技术驱动新药研发的国际性生物技术公司，今日宣布其合作伙伴NEOK Bio, Inc.近日获得美国食品药品监督管理局（FDA）对其在研新药NEOK002的新药临床试验申请（IND）批准。NEOK002是一款靶向EGFR/MUC1的抗体偶联药物（ADC），拟用于实体瘤治疗。NEOK Bio计划于2026年第二季度启动I期临床试验，并预计于2027年公布初步临床数据。 此次IND获批标志着NEOK002项目取得重要里程碑进展。NEOK002基于百奥赛图自主开发并于2024年对外授权的双特异性抗体构建，由NEOK Bio进一步推进ADC药物开发。根据NEOK Bio披露，NEOK002面向实体瘤治疗开发，相较于仅靶向单一抗原的ADC药物，有望在疗效与安全性方面展现差异化优势。 百奥赛图董事长兼CEO沈月雷博士表示：“我们非常高兴看到合作项目推进至这一重要阶段。此次里程碑的达成，进一步验证了基于RenLite®...

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Driven Brands Holdings Inc. (“Driven Brands” or the “Company”) (NASDAQ:DRVN) investors of the May 8, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual inve...

WALLA WALLA, Wash.--(BUSINESS WIRE)--The Banner Bank leadership team announces the promotion of Jennifer Krug to Executive Vice President and Enterprise Operations Executive. In this role, Krug will continue leading the Bank’s enterprise operations, supporting strong execution, operational excellence, and scalable infrastructure aligned with Banner’s long-term strategic objectives. “Elevating Jennifer to an executive-level leader recognizes her strategic vision, operational discipline and focus...

HOUSTON--(BUSINESS WIRE)--A SLB (NYSE:SLB) realizará uma teleconferência no dia 24 de abril de 2026 para discutir os resultados do primeiro trimestre encerrado no dia 31 de março de 2026. A teleconferência está agendada para começar às 11h00, horário do leste dos EUA, e um comunicado de imprensa sobre os resultados será divulgado às 7h00, horário do leste dos EUA. Para acessar a teleconferência, os participantes devem entrar em contato com a operadora pelo telefone +1 (833) 470-1428 (dentro da...

SAN FRANCISCO--(BUSINESS WIRE)--  Rubedo Life Sciences annonce les résultats préliminaires positifs de l’essai clinique de phase 1 portant sur son candidat-médicament principal, RLS-1496, mené auprès de patients atteints de psoriasis en plaques, de dermatite atopique ou présentant des signes de vieillissement cutané Rubedo Life Sciences, Inc. (Rubedo), une société de biotechnologie alimentée par l’intelligence artificielle et opérant au stade clinique, spécialisée dans la découverte et le dével...